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1. Introduction 
Human Papillomavirus (HPV) are epitheliotropic for stratified malpighian epithelia such as 
those of the cervix, vulva or anal canal. Mucosal papillomaviruses are responsible for 
several clinical lesions and can be classified as non oncogenic and oncogenic viruses. The 
first ones are responsible for benign lesions such as external genital warts (EGW) or 
condyloma due to HPV 6 and 11. The second ones include oncogenic viruses such as HPV 
16 and 18, the most common ones, and HPV 45, 31, 33, 52 etc which are involved in invasive 
cancers preceded by cervical, vulvar, penile or anal intraepithelial neoplasia. Oncogenic 
HPV are detectable in 99.7% of cervical cancers (Bosch et al, 1995). Cellular immunity plays 
a key role in controlling and killing infected or transformed keratinocytes. Nevertheless, 
around 10% of women having infected cervical mucosa are not able to control oncogenic 
HPV and develop cervical intraepithelial neoplasia (CIN). High grade CIN (CIN3) require 
surgical treatment before their progression to invasive cancers in 30% of cases (McCredie et 
al, 2008; Ostor et al, 1993). A great priority is then to develop a preventive vaccine to protect 
against HPV infection. In women with CIN, therapeutic vaccine could be used to eliminate 
previously infected or transformed keratinocytes and avoid surgical treatment.  
2. Virology 
Following a breach in the malpighian pluristratified epithelium, HPVs infect basal stem cells 
of keratinocytes. The virus initially remains in episomal form with synthesis of E2 protein. 
This protein is a major regulator of viral vegetative cycle and is required for transcriptional 
regulation as well as viral DNA replication together with the E1 helicase (Desaintes et al, 
1996). In contrast, E2 is generally undetectable in cancers due to a preferential integration of 
the viral genome in the cell genome and disruption of the E2 open reading frame (Berumen 
et al, 1994; Collins et al, 2009). Therefore E2 is a marker of viral infection and is specific for 
the early stages of the viral gene expression in infected cells. This was formally 
demonstrated in a recent work that showed a strong staining of the E2 protein in the 
intermediate differentiated layers of HPV16-infected tissues and low grade CIN (Xue et al, 
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2010). The high expression of HPV16 E2 in low grade lesions therefore represents a marker 
for HPV infection even before any clinical manifestation.  
After integration of the genome of oncogenic HPVs into the host genome, viral oncogenic E6 
and E7 proteins are synthesized in large quantities in the inner third of the epithelium. 
During maturation of keratinocytes from the basal layer to the epithelial surface, viral 
capside proteins L1 and L2 are synthesized and expressed at the surface of mature 
keratinocytes in order to form a new viral particle which is able to infect adjacent healthy 
epithelium and to contaminate sexual partners.  
3. Epidemiology of oncogenic HPV and related diseases 
HPV infections occur preferentially in young women under 25 years of age (Boulanger et al, 
2004). Several stages of lesions can be observed following oncogenic HPV infection. The first 
stage is a simple infection of keratinocytes that become koilocytes and develop into 
condyloma. The following stages are related to the transformation of infected keratinocytes 
into malignant cells. The depth at which malignant cells are found defines the disease stage: 
low (as CIN1) or high grade squamous intraepithelial lesions as CIN2/3. The latter is 
diagnosed on the basis of Pap smears, followed by colposcopy and biopsies and can evolve 
towards invasive cancer. HPV16 is found in more than 50% of cervical cancer cases and 
HPV18 in 17%. The incidence of cervical cancer remains very high with 500 000 new cases 
per year in the world, essentially in developing countries where the level of screening by 
Pap smear is very low. It annually leads to 230 000 deaths.  
The premalignant lesions of HPV-related grade 3 usual vulvar intraepithelial neoplasia 
(usual VIN or VIN3) involve the mucosal and/or cutaneous epithelium of the vulva, 
perineal and perianal region. Usual VIN occurs in adult women and commonly resembles 
persistent anogenital warts that are often multifocal pigmented papular lesions 
disseminated on the vulva and/or the perianal skin. Usual VIN is characterized by the 
presence of poorly differentiated or undifferentiated basal cells and highly atypical 
squamous epithelial cells (McClugagge et al, 2009). The oncogenic HPV most frequently 
found in usual VIN is HPV16 that plays a direct role in up to 91% of the cases (Srodon et al, 
2006).  
The overall incidence rates of anal cancer has recently increased, particularly among men 
who have sex with men (MSM) and HIV-infected patients (Piketty et al, 2008) Combination 
antiretroviral therapy does not prevent nor revert anal cancer in the latter patients (Piketty 
et al, 2010). Despite several HPV coinfections in particular in HIV-infected patients, HPV16 
is the most common one in anal cancer (Abramowitz et al, 2011). 
4. Humoral immune response after HPV infection 
Serum antibodies against HPV are directed against viral capside antigens and in 
particular against L1 protein. Their synthesis is late (6 to 12 months after infection) and 
antibody concentration remains limited because of the absence of HPV viremia (Carter et 
al, 2000). However, these antibodies persist in many women for at least 10 years (af 
Geijersstam et al, 1998). Only 70% of women having persistent HPV16 DNA in the genital 
www.intechopen.com
Current Insight into Anti-HPV Immune Responses  
and Lessons for Prophylactic and Therapeutic Vaccines 127 
mucosa have detectable antibodies (Ho et al, 2004; Kirnbauer et al, 1994). These antibodies 
do not play any neutralizing role against HPV after virus entry in basal stem cells of 
keratinocytes (de Gruijl et al, 1999) because L1 protein is not expressed at the surface of 
these cells.  
5. Antibodies detected after HPV infection do not protect against a new 
infection  
Antibodies synthesized after HPV infection do not protect against a new infection with the 
same HPV genotype, as observed in a cohort study of women with and without such 
antibodies (Viscidi et al, 2004, 2005). There was no difference over time between the two 
groups with respect to HPV16 DNA detection in the genital mucosa. This is not surprising 
since the level of the anti-HPV antibodies found in mucosal secretions is lower than in the 
serum where the level of antibodies is already very low (Lowe et al, 1997; Nardelli-Haefliger  
et al, 2003). Local secretory IgA could not stop the spread of HPV infection (Bard et al, 2004). 
6. Cellular immune response after HPV infection 
Cellular immune responses play a critical role in HPV infections by controlling or 
eliminating the virus. The incidence of HPV-induced diseases is increased in T-cell 
immunodeficient individuals, such as HIV-infected (Sun et al, 1997), transplanted patients 
(Arends et al, 1997), patients treated by immunosuppressive drugs (Ulrich et al, 2008) or in 
primary immunodeficiencies (Lawrence et al, 2005). In patients with high-grade CIN 2/3 or 
invasive cervical carcinoma, blood cytotoxic T lymphocytes (CTL) directed against HPV-16 
E6 or E7 proteins are barely detectable (Nakagawa et al, 1997, 2000). Proliferative responses 
of CD4-lymphocytes against these two proteins seem to correlate with the infection stage. 
Indeed, high frequency specific interleukin-2 (IL2)–producing CD4 lymphocytes have been 
observed in asymptomatic HPV-16–infected women (de Jong et al, 2002) whereas they 
decrease during disease progression toward high-grade CIN or invasive cancer (Tsukui et 
al, 1996).  
In a woman who completely cleared usual vulvar intraepithelial neoplasia (VIN) lesions 
eight months after disease onset (Figure 1), an immunohistochemical study showed a 
marked dermal infiltrate containing a majority of CD4+ T lymphocytes and an epidermal 
infiltrate made up of both CD4+ and CD8+ T cells (Figure 2) (Bourgault Villada et al, 2004). 
Before clinical regression, high frequency anti-E6 and anti-E7 effector blood T-cells by ex vivo 
IFNγ ELISPOT assay was evidenced (Figure 3). This appears to be the first evidence of an 
association between spontaneous regression of usual VIN lesions and HPV-specific T cell 
responses detectable in the blood. Hence, an increase of HPV-specific effector T lymphocyte 
responses by vaccine-based therapeutic strategies might be useful to clear the lesions in 
usual VIN disease.  
On the contrary, in chronic nonregressive CIN3, lymphocyte infiltrates in the epidermis 
mainly contain CD8+ lymphocytes and no CD4+ cells. It is likely that CD8+ lymphocytes 
play a major role in the defense against HPV infections by killing infected keratinocytes. 
However, CD4+ lymphocytes that synthesize IFNγ and IL2 are required for an optimal 
induction of high affinity tumor-specific memory CD8+ effector T-cells. 
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Fig. 1. Clinical lesions of multifocal pigmented usual VIN before spontaneous clinical 
regression 
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Fig. 2. Immunohistochemical study of the vulvar biopsy just before spontaneous regression 
 
 
Fig. 3. IFNγ ELISPOT assay performed just before clinical regression 
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7. Presentation of HPV antigens to T and B lymphocytes after HPV infection  
During infection, viral particles enter through epithelium up to basal basal stem cells of 
keratinocytes and sometimes can penetrate into the chorion. In the epithelium, they can be 
captured by Langerhans cells and they are quickly internalized (Bousarghin et al, 2005; 
Fausch et al, 2005; Malejczyk et al, 1997) and degraded into short and large peptides 
(Combadière et al, 2008; Herbst et al, 1996; Offringa et al, 2003; Yan et al, 2004). The classical 
view of the role of Langerhans cells is one of antigen uptake in the epidermis, and migration 
through the dermal lymphatics to the lymphoid organs, where they present antigen to 
lymphocytes that then home back to the tissue to carry out their effector function. Matthews 
et al (2003) have previously reported that Langerhans cells number is significantly reduced 
in HPV16 lesions without Langerhans cells depletion in the surrounding uninfected tissue. 
During HPV infection, the migration of Langerhans cells towards mucosal follicle is 
followed by presentation of short and large viral peptides by HLA class I and HLA class II 
molecules to CD4+ and CD8+ T lymphocytes, respectively. After stimulation, CD4+ and 
CD8+ T lymphocytes can circulate and migrate within the HPV-infected epithelium by 
using their surface molecules such as cutaneous lymphocyte antigen (Grover et al, 2006). 
The presentation of whole viral particles to B lymphocytes requires that HPV binds to 
dermal dendritic cells that are able to carry the whole virus to follicular dendritic cells 
present in mucosal follicle (Palucka et al, 2010). 
8. Does a T-cell marker of viral control exist?  
We recently tested by proliferative assays, intracellular cytokines synthesis and IFNγ 
ELISPOT the cellular immune responses against the HPV16 E2 protein that is early 
synthesized after HPV infection when the virus is episomal in eight women presenting with 
HPV16-related usual VIN and their healthy male partners (Jacobelli et al, 2011, unpublished 
data). We showed that anti-E2 polyfunctional CD4 T-cell responses (proliferative responses 
and synthesis of IFNγ and/or IL2) appear when the clinical lesions heal or when the HPV 
infection remains silent. Blood proliferative T-cell responses against HPV16 E2 peptides 
have been also observed in 50% of healthy women, who presumably previously cleared 
HPV16 infection (de Jong et al, 2004) and in 9 out of 22 regressive CIN3 cases (Dillon et al, 
2007). In another studies, the lack of anti-E2 proliferative responses was reported in 16 of 18 
patients (89%) affected with usual VIN lesions (Davidson et al, 2003) and in 7 of 8 and 9 of 
12 women affected with CIN3 (Dillon et al, 2007; de Jong et al, 2004). These observations 
reinforce the strong role of T-cells in the control of HPV replication. 
9. Why the male partners of women having CIN3 or usual VIN do not have any 
lesion?  
Men are vectors of oncogenic HPV infection (Buckley et al, 1981). However, while HPV 
infection was found in 71 to 90% of the partners of HPV-infected women (Hippelainen et al, 
1994; Nicolau et al, 2005), only 52% harbored the same HPV subtypes (Reiter et al, 2010). 
Moreover, penile intra-epithelial neoplasia is rare and detected in less than 2% of the men in 
contact with oncogenic HPV (Giraldo et al, 2008). We thus analyzed HPV infection and anti-
HPV16 E2 blood T-cell responses in asymptomatic male partners chronically exposed to 
HPV16 during sexual intercourses with their wives affected with usual VIN (Jacobelli et al, 
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 130 
2011, , unpublished data). We had hypothesized that male partners exposed to replicative 
HPV16 could develop immunologic responses against the early E2 viral protein and thus 
clear infection. We indeed observed HPV16-E2-specific proliferative responses and 
intracellular synthesis of single IFNγ, dual IFNγ/IL2 and single IL2. These T-cell responses 
indicate a striking link between the absence of HPV-related lesions and the presence of 
spontaneous anti-E2 specific polyfunctional T-cell response in male partners. It is tempting 
to speculate that E2-specific responses prevent HPV16-related lesions. Since E2 protein is 
not encapsidated in the viral particle, the strong E2-specific T cells responses measured in 
partners of women with usual VIN demonstrates that the virus effectively replicates in 
males. Our results suggest that male are an important reservoir of genital HPVs and provide 
a strong argument in favor of prophylactic HPV vaccination of young men with Virus Like 
Particles to decrease HPV16 infection in men, and thus fight against the spread of mucosal 
HPV diseases in the population.  
10. Balance between cellular immunity and infected / tumoral cells: 
Mechanisms of tumor escape 
The impairment of HPV-16–specific CD4 lymphocytes and CTL responses can occur many 
years after infection / transformation of keratinocytes. It could be related to the tumor or to 
T-cell responses. The tumor cells can down-regulate their MHC class I molecules, synthesize 
TGFβ or decrease the number of viral peptides on their surface. Mechanisms of T-cell 
tolerance to HPV includes presence of regulatory T-cells (Treg) at proximity of the tumor 
cells (van der Burg et al, 2007) and sometimes in the blood (Molling et al, 2007; Visser et al, 
2007), engagement of PD1 or CTLA4 in the immune synapse and inhibition of CD3 zeta 
expression on infiltrating tumor T-cells (Patel et al, 2009; Zehbe et al, 2006). 
11. Prophylactic vaccines can prevent infection 
The vaccination against HPV can have two different purposes. The first one is a preventive 
strategy aiming at blocking primary infection by preventing the entry of the virus into their 
target cells i.e. the basal basal stem cells of keratinocytes. In this aim, a vaccination able to 
induce transudated serum antibodies at the epithelial surface is a good strategy and is 
obtained by using viral L1 particles as vaccine. Large quantities of L1 are produced in vitro 
by splicing the L1 gene into plasmids (for expression in yeast) or recombinant baculoviruses 
(for expression in insect cells). The Virus Like Particle is formed by self aggregation of 72 L1 
capsomers into a sphere. This spherical structure is similar to the viral capside, but it is 
empty without DNA or RNA and non infectious. After systemic immunization, it is able to 
induce the synthesis of neutralizing antibodies that can recognize the conformational 
structure of the real viral capside. Inversely, after HPV infection, antibodies are ineffective 
and only therapeutic vaccines can be considered to induce T lymphocytes able to kill HPV 
infected keratinocytes. These therapeutic vaccines must target oncogenic E6 and E7 viral 
proteins early expressed in the basal epithelial cells.  
Merck has developed Gardasil®, a vaccine directed against four HPV types. It contains 
Virus Like Particles (L1) from HPV-6, 11, 16, and 18, with aluminum hydroxyphosphate as 
an adjuvant. Cervarix® is a bivalent vaccine developed by GSK. It targets HPV-16/18 VLP 
(L1) and contains a novel adjuvant named ASO4 co-formulated with aluminum. ASO4 
contains phospholipids from Salmonella minnesota membrane and binds to TLR4 at the 
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surface of dendritic cells. Activated dendritic cells synthesize type I IFN, IL6, IL12, TNFα 
that allows recruitment and stimulation of Th follicular cells that increase antibodies 
production by B lymphocytes.  Both vaccines must be administrated by intramuscular route. 
Three injections should be performed, at M0, M2 and M6 for Gardasil® and M0, M1 and M6 
for Cervarix®. Gardasil® and Cervarix® have been commercialized worldwide and each 
country should define their own recommendations. 
Phase I trials of Gardasil® were performed with only HPV16 L1 VLP in 300 16 to 23 years old 
women, who had less than 5 sexual partners and had never been exposed to HPV16 (Harro et 
al, 2001). The immunogenicity of the vaccine was excellent with the induction of very high 
levels of blood anti-L1 antibodies, 50 to 100 times those observed after natural HPV infection. 
The tolerance of the vaccine was good with only a slight pain, swelling and erythema at the 
injection sites. Phase II trials included about 2 000 subjects, they showed preliminary proof of 
efficacy using also HPV16 VLP versus a placebo (Koutsky et al, 2002). Subsequent phase III 
trial were carried out on more than 25 000 subjects, using the quadrivalent vaccine containing 
VLP from HPV 6, 11, 16 and 18. 98 to 100% protection was obtained against HPV -6, 11, 16, and 
18 related diseases such as CIN2/3, vulvar and vaginal condyloma, usual VIN and VaIN3 
(Garland et al, 2007; Joura et al, 2007; Munoz et al, 2010). Protection against persistent infection 
(for 6 months) by HPV16 or 18 was obtained in 99% of cases. Gardasil® obtained an FDA 
approval for the vaccination of girls and women aged 9 to 26 years to prevent cervical cancer, 
precancerous genital lesions and genital warts. Recently, 90% protection was obtained against 
extragenital warts in males (Giuliano et al, 2011). Efficacy of Gardasil® obtained against 
HPV31-induced CIN2/3 is around 55%. Finally, 43% protection was obtained against CIN2/3 
induced by 14 oncogenic and non oncogenic genotypes of HPV (HPV 6, 11, 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59) 3.7 years after vaccination.  
As for Cervarix®, phases I and II (Harper et al, 2004, 2006) studies showed 98 to 100% 
protection against CIN 2/3 similar to that of Gardasil®. The phase III trial involved more 
than 20 000 subjects (Paavonen et al, 2007) and was approved by the FDA and European 
Medical Agency. 70% protection was obtained against CIN2/3 related to 14 oncogenic HPV 
genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) 3 years following 
vaccination (Paavonen et al, 2009). The efficacy of Cervarix® against HPV31-induced 
CIN2/3 is around 92%. Protection against persistent infection (for 6 months) by HPV33 and 
45 was obtained in 76 and 77% of cases respectively.  
Nevertheless, many questions remain unanswered. How long will the protection last ? Does 
thresholds of antibodies exist to allow the protection ? What will be the impact of the 
vaccination on the ecology of other HPVs, HPV screening by Pap smears and on adolescent 
sexual behavior and their use of condoms for HIV protection ? Will parents, preteens, 
physicians and the public at large, accept vaccination of young girls ? Will it be interesting 
to vaccinate young men to decrease HPV16 infection in men, viral transmission from men to 
women and more importantly spread of mucosal HPV diseases in the population ? Are 
MSM the future candidates for vaccination against anal cancer ?  
12. Protection by the quadrivalent prophylactic vaccine against cutaneous 
external genital warts  
A paradox exits between the protection by prophylactic vaccines against cutaneous EGW 
(related to HPV6 and 11 replicative viruses) and the absence of detectable antibodies on the 
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keratinized  skin surface. Following a breach in the epithelium, HPVs bind via L1 first to the 
basement membrane and then to the cellular receptor on the basal stem keratinocytes (Kines 
et al, 2009). Anti-L1 antibodies induced by prophylactic vaccines could block both of these 
interactions (Day et al, 2007). Indeed, this process of virus entry is slow, between 12 to 14 
hours (Sapp et al, 2009) and, since the breach is accompanied by a serum exudate, exposure 
to serum antibodies is rapid. Another explanation for protection could be a stronger 
stimulation of anti-HPV CD4+ and CD8+ T-cells after infection. Indeed, in the presence of 
memory anti-L1 CD4+ T-cell, the CD8+ cytotoxic T-lymphocytes could be more strongly 
stimulated, with multiple specificities and higher affinity (Sauzet et al, 1995). The killing of 
infected keratinocytes could be then more effective. 
13. Prevention of infection by other oncogenic HPVs by divalent prophylactic 
vaccine  
Recently, it has been demonstrated that Cervarix® is able to prevent CIN2/3 induced by 
HPV 16 and 18 and also by HPV 31, 33 and 45 (http://www.ema.europa.eu/, cervarix®, 
summary of product characteristics). An efficacy of 70% and 43% was obtained against 
CIN2/3 related to 14 oncogenic HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) with 
Cervarix® and 12 oncogenic HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) with 
Gardasil®, respectively (http://www.ema.europa.eu/, gardasil®, summary of product 
characteristics). A high level of anti-HPV antibodies usually correlates with a broad 
recognition of B-cell epitopes. Such epitopes can be shared by several other closely related 
HPVs. In Cervarix®, the use of ASO4 adjuvant allows to obtain high anti-HPV16 and 18 
antibodies levels, that are able to prevent infection by numerous other oncogenic HPVs 
(McKeage et al, 2011).  
14. Alternative to L1 VLP vaccines 
A particularly attractive strategy is to vaccinate with a linear N-terminal highly conserved 
sequence of the viral capsid L2 protein. In a properly immunogenic context, neutralizing 
antibodies to this B cell epitope-containing region are elicited and they have broadly 
neutralizing capacities against a wide range of HPVs (Conway et al, 2011). Immunization 
with adjuvanted chimeric HPV16L1-HPV16L2 VLP have also induced neutralization or 
cross-neutralization of HPV16, -18, -31, -45, -52, and -58; HPV6 and -11; and HPV5 
(Schellenbacher et al, 2009). These new types of vaccine are very promising. 
15. How to cure infection / tumorigenesis? Therapeutic vaccines 
Preventive vaccines do not address the current need for better treatment for women 
previously infected by HPV 16 or 18. Other types of vaccines must be used to increase or 
induce new specific anti-HPV cellular immunity (CD4+ and CD8+ T lymphocytes) in order 
to kill transformed epithelial cells. Several approaches can be used in this aim. To stimulate 
cytotoxic or antiviral CD8+ T lymphocytes, the vaccines must target the cytoplasm of 
dendritic cells. The degradation of vaccine antigens by proteasomes results in short peptides 
that can bind to HLA class I molecules and migrate at the surface of dendritic cells. To 
stimulate CD4+ T lymphocytes, endocytosis of vaccinal antigens is essential, followed by 
degradation of antigens by lysosome/endosome in large peptides that associate with HLA 
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class II molecules before migrating at the surface of dendritic cells. All these therapeutic 
vaccines must target E6 and E7 viral proteins and contain recombinant viruses (vaccinia 
viruses for example), DNA or peptides.  
Peptidic or lipopeptidic vaccines were tested within phases I-II for treatment of women 
having CIN3 or metastatic cervical cancer. The chosen peptides were E7 11-20 and E7 86-93, 
two peptides able to bind HLA-A2 molecules in association with a CD4+ epitope (PADRE) 
able to bind numerous HLA-DR molecules (Ressing et al, 2000; Steller et al, 1998; van Driel 
et al, 1999). In women with invasive cervical cancer, 25 to 30% of cellular immune responses 
were observed without any clinical improvement. Another trial in 18 women with CIN3 has 
shown a clinical improvement in 50% of them (Muderspach et al, 2000). Recently, an open 
clinical trial was performed by the Melief’s group (Kenter et al, 2009) in twenty women 
presenting with usual VIN using 13 large peptides spanning the whole E6 and E7 proteins. 
Forty five percent of complete (9/20 women) and 25 % (5/20) of partial remission were 
observed 12 months after immunization. These important results would be even more 
interesting if the investigators had included a placebo group (Bourgault Villada, 2010a). A 
new trial with a placebo group is currently under way.  
Vaccinia virus was used in a recombinant vaccine containing E6 and E7 genes from HPV16 
and HPV18 (TA-HPV) to vaccinate usual VIN patients. A clinical complete or partial 
response was observed in 8/18 treated women (Davidson et al, 2003). More recently, 
vaccination against usual VIN was also performed with another recombinant vaccinia virus, 
TA-L2E6E7 from HPV16 (Daayana et al, 2010). Two months before vaccination, 19 women 
were treated by topical imiquimod and then vaccinated by intramuscular route with 3 doses 
of recombinant vaccinia virus. Imiquimod is an immunomodulator that increases the 
synthesis of type I IFN by dendritic cells after its fixation to the TLR7 in human dendritic 
cells. Complete remission was obtained in 58% of vaccinated women.  
Vaccination against CIN 2/3 was also performed by Transgene using a recombinant 
vaccinia virus, MVA, associated with the genes coding for E6 and E7 proteins and IL2 
cytokine in 18 women. The disappearance of the lesions was observed by colposcopy 6 
months later in 10 patients, without any CIN at biopsy in 9 cases. The important conclusion 
of this trial was that the vaccine was clinically effective, thus avoiding conization for 50% of 
the women with HPV16-related CIN2/3. A phase II trial including a placebo group is 
presently undertaken.  
A phase II clinical trial has also been performed to evaluate the potential use of the MVA-E2 
in treating CIN 2/3 (Garcia-Hernandez et al, 2006). Thirty-four women received the 
therapeutic vaccine injected directly into the cervix once every week over a 6-week period. 
Nineteen patients (59%) showed no lesion nine weeks later and histological analysis showed 
total elimination of high-grade lesions in 20 patients. All patients developed Ab against the 
MVA-E2 vaccine and showed a specific cytotoxic response against papilloma-transformed 
cells.  
DNA containing E6 and E7 genes from HPV 16 and 18 (ZYC101a) was administered on 86 
women having CIN2/3 (Garcia et al, 2004). Conization was performed 6 months later. 
Resolution of CIN was observed in 73% of the younger (less than 25 years old) women with 
a significant difference compared to a control group. This therapeutic vaccine is also very 
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promising as CIN 2/3 treatment. New phase II trial is currently under way, testing DNA 
from E6 and E7 genes versus placebo.  
All these results are very important and encouraging for the development of therapeutic 
vaccines for HPV induced cancers. Nevertheless the proof of efficacy in CIN 2/3 should be 
carefully demonstrated because therapeutic vaccine should be more efficient that surgery. It 
is important to note that these therapeutic vaccines should avoid relapse of HPV infection 
after treatment by increasing HPV-specific cellular immunity.   
Other vaccines were tested to fight high grade anal intraepithelial neoplasia (AIN3) in HIV+ 
patients. HSPE7 including Mycobacterium bovis BCG heat-shock protein 65 (Hsp65) and 
HPV16 E7 protein was tested. Clinical complete and partial responses were observed in 5 
vaccinated patients out of 15 (33% of efficacy) (Palefski et al, 2006). A better vaccine with 
adjuvant is presently developed.  
The safety and immunogenicity of the human papillomavirus type 16 (HPV16) or HPV18 
(HPV16/18) E7 protein-pulsed mature dendritic cell vaccination (phase I) were evaluated as 
adjuvant therapy for 10 patients with stage IB cervical cancer treated by radical 
hysterectomy (Santin et al, 2008). All patients developed CD4+ T-cell and Ab responses to 
DC vaccination and 8 of them E7-specific CD8+ T-cells. DC vaccination was well tolerated 
and no significant toxicity was recorded. New trials (phase II) in cervical cancer patients 
harboring a limited tumor burden or who are at significant risk of tumor recurrence are 
warranted to show an efficacy of this immunotherapy.  
Condyloma have been also treated by immunotherapy. Two trials were performed using the 
VLP of HPV6 (Zhang et al, 2000) or the fusion protein L2E7 fron HPV6 (Lacey et al, 1999; 
Thompson et al, 1999; Vandepapeliere et al, 2005) with a clearance of condyloma obtained in 
75 and 20% of cases, respectively. In the absence of control group in these trials, it is too 
early to make conclusions about the efficacy of these vaccines. In a phase I/II trial, thirty 
males presenting with intraurethral flat condyloma were treated with either a recombinant 
vaccinia viral vaccine MVA-E2 (expressing the E2 gene of bovine papillomavirus) (Albarran 
et al, 2007). 28/30 patients treated with MVAE2 vaccine were free of clinical or histological 
lesion or HPV at 4 weeks. 
16. How to determine the epitopic regions for a therapeutic vaccine?  
In a study including 16 women presenting with usual VIN, we have determined the 
strongly immunogenic regions from HPV16 E6 and E7 proteins for CD4+ and/or CD8+ T 
lymphocytes (Bourgault Villada et al, 2010b). Among 18 large peptides of the proteins E6 
and E7, two were recognized in proliferative assays as immunodominant by T cells from 10 
out of 16 women (62%) at the entry in the  study, namely E6/2 (aa 14-34) and E6/4 (aa 45-68) 
peptides. Four other peptides, E6/7 (aa 91-110), E7/2 (aa 7-27), E7/3 (aa 21-40) and E7/7 (aa 
65-87) were recognized by only 12% of the women in proliferative or IFNγ ELISPOT tests. 
The regions of E6 and E7 proteins implicated in T cell recognition during HPV infection 
were not yet well defined because of the usually low frequency of anti-HPV blood T cell 
responses and of the difficulties of their study.  
In protein E6, some peptides included in, including or overlapping our peptides E6/2 (aa 
14-34) and E6/4 (aa 45-68) have already been described as preferentially recognized by 
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CD4+ T cells. Among them, peptide E6 42-57 that is restricted by HLA-DR7 has already 
been identified (Strang et al, 1990). Regions E6 1-31, 22-51 and 24-45 can be also 
immunogenic for CD4+ T cells as shown in CIN or sexually active healthy women (Kadish et 
al, 1997). The region E6 42-71, which includes peptide E6/4 (aa 45-68), has also been 
described as a target of proliferative responses in CIN patients (Kadish et al, 1997). Another 
E6 111-158 region was previously described as inducing proliferative responses in infected 
asymptomatic subjects or in patients with CIN3 (Kadish et al, 1997; Strang et al, 1990) as 
well as E6 127-141 peptide in healthy young women (Gallagher et al, 2007). Similarly, 
peptides E7 43-77, E7 50-62 and E7 58-68 which are restricted by DR3, DR15 and DR17, 
respectively, were defined as epitopic peptides for CD4 + T cells (Strang et al, 1990; van der 
Burg et al, 2001; Wang et al, 2009). E7 region 51-98, including our E7/7 (aa 65-87) peptide, is 
also very immunogenic for proliferating T lymphocytes (de Gruijl et al, 1998; Luxton et al, 
1996; Nakagawa et al, 1996).  
The characterization of E6 and E7 HPV-16 epitopes and the HLA restriction of their 
recognition by CD8+ T lymphocytes are more precise: E6 29-38, E7 11-20, E7 82-90 and E7 
86-93 epitopes are presented by HLA-A2 (Evans et al, 2001; Ressing et al, 1995, 1996), E6 80-
88 and E7 44-52 by HLA-B18 (Bourgault Villada et al, 2000) and E6 49-57 by HLA-A24 
(Morishima et al, 2007). In women who cleared HPV 16 infection, cytotoxic T lymphocytes 
(CTL) responses are directed against epitopes preferentially located in the N-terminal half of 
the E6 protein (region 16-40) (Nakagawa et al, 2005). In this fragment, the dominant epitope 
E6 29-37 is restricted by HLA-B48, E6 31-38 by HLA-B4002 and the subdominant epitope E6 
52-61 by HLA-B35 (Nakagawa et al, 2007). The same group had also shown that the peptide 
E6 33-42 61 is recognized by CD8+ T lymphocytes in association with HLA-A68, peptide E6 
52-61 in association with HLA-B57 and –B35, peptide E6 75-83 in association with HLA-B62, 
peptide E7 7-15 in association with HLA-B48 and peptide E7 79-87 in association with HLA-
B60 (Nakagawa et al, 2004, 2007; Wang et al, 2008). In addition, E7 7-15 is also able to bind 
HLA-A2 and -B8 to be recognized by CTL (Oerke et al, 2005; Ressing et al, 1995). From the 
latter results, two hot spots of CD8+ T-cell epitopes in protein E6 may be located in the 
regions E6 29-38 and 52-61 and another one in protein E7 (E7 7-15) (Nakagawa et al, 2007). 
Nevertheless, a poor immunogenicity of E7 protein was observed in many studies during 
both HPV 16 infection and after peptidic vaccination using long peptides spanning both E6 
and E7 (Kenter et al, 2008; Welters et al, 2008) such as those used in our study. 
The epitopes E6/2 (aa 14-34) and E6/4 (aa 45-68) hence could be strongly recognized by 
CD4+ and / or CD8+ T lymphocytes and could be particularly relevant in the design of a 
peptide vaccination. We may hypothesize that the T cell responses that we observed were 
able to contain the tumor cells into the epithelium. Therefore, E6/2 (aa 14-34) and E6/4 (aa 
45-68) peptides could play a major role in the protection against invasive cancer by 
stimulating T lymphocytes.  
17. Conclusion 
HPV infections are very frequent. Eighty percent of women more than 25 years old have 
been infected. Two third of them have been infected by a oncogenic HPV and 10% of them 
will develop an intraepithelial neoplasia, mainly CIN. Preventive vaccines are very effective 
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means of avoiding CIN and cervical cancer with an efficacy of 70% against CIN 2/3 related 
to 14 oncogenic HPVs. Some questions persist about this preventive vaccine: How long will 
the protection last ? Boosts will be necessary ? Young boys should be also vaccinated ? What 
is the best age to perform the vaccine with the highest immunogenicity ?  
Women previously infected by HPV 16 or 18 and presenting with intraepithelial neoplasia 
are not good candidate for prophylactic vaccines. Therapeutic vaccines should be good 
alternatives to surgery for CIN2/3, VIN3 and AIN3 and they are being continuously 
improved.  
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